N
Nancy F. Olivieri
Researcher at University of Toronto
Publications - 228
Citations - 16364
Nancy F. Olivieri is an academic researcher from University of Toronto. The author has contributed to research in topics: Thalassemia & Deferoxamine. The author has an hindex of 65, co-authored 226 publications receiving 15697 citations. Previous affiliations of Nancy F. Olivieri include McMaster University Medical Centre & Mount Sinai Hospital, Toronto.
Papers
More filters
Journal ArticleDOI
Iron-chelating therapy and the treatment of thalassemia
TL;DR: The toxicity of this agent mandates a careful evaluation of the balance between risk and benefit of deferiprone in patients with thalassemia, in most of whom long-term deferoxamine is safe and efficacious therapy.
Journal ArticleDOI
Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment
Martin H. Steinberg,Martin H. Steinberg,Franca B. Barton,Oswaldo Castro,Charles H. Pegelow,Samir K. Ballas,Abdullah Kutlar,Eugene P. Orringer,Rita Bellevue,Nancy F. Olivieri,James R. Eckman,Mala Varma,G. Ramirez,Brian Adler,Wally R. Smith,Timothy M. Carlos,Kenneth I. Ataga,Laura DeCastro,Carolyn Bigelow,Yogen Saunthararajah,Margaret Telfer,Elliott Vichinsky,Susan Claster,Susan Shurin,Kenneth Bridges,Myron A. Waclawiw,Duane Bonds,Michael L. Terrin +27 more
TL;DR: In a long-term observational follow-up study of mortality in patients with SCA who originally participated in the randomized, double-blind, placebo-controlled Multicenter Study of Hydroxyurea in Patients with Sickle Cell Anemia (MSH), conducted in 1992-1995, to determine whether hydroxyuraxurea attenuates mortality in Patients With SCA as discussed by the authors.
Journal ArticleDOI
Survival in medically treated patients with homozygous beta-thalassemia.
Nancy F. Olivieri,David G. Nathan,James H. MacMillan,Alan S. Wayne,Peter P. Liu,Allison McGee,Marie Martin,Gideon Koren,Alan R. Cohen +8 more
TL;DR: Univariate analysis demonstrated that factors affecting cardiac disease-free survival were age at the start of chelation therapy and life-table analysis to estimate freedom from cardiac disease over time.
Journal ArticleDOI
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.
Maria Domenica Cappellini,Alan R. Cohen,Antonio Piga,Mohamed Bejaoui,Silverio Perrotta,Leyla Agaoglu,Yesim Aydinok,Antonis Kattamis,Yurdanur Kilinç,John B. Porter,Marcello Capra,Renzo Galanello,Slaheddine Fattoum,Guillermo Drelichman,Carmelo Magnano,Mônica Pinheiro de Almeida Veríssimo,Miranda Athanassiou-Metaxa,Patricia J. Giardina,Alexandra Kourakli-Symeonidis,Gritta Janka-Schaub,Thomas D. Coates,Christiane Vermylen,Nancy F. Olivieri,Isabelle Thuret,Herbert Opitz,C. Ressayre-Djaffer,Peter W. Marks,Daniele Alberti +27 more
TL;DR: A comparative phase 3 trial was conducted to demonstrate the efficacy of deferasirox in regularly transfused patients with beta-thalassemia aged 2 years or older, and found it to be a promising once-daily oral therapy for the treatment of transfusional iron overload.
Journal ArticleDOI
The β-Thalassemias
TL;DR: Thalassemia is a disease of Mediterranean origin occurring in children of Italian origin and associated with splenomegaly and characteristic bone changes not confined to the Mediterranean, but occurring widely.